Investigational drug · Phase 2
Checkpoint Inhibitor
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumor, Adult, Cancer, Neoplasms.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
1,052
Any phase or sponsor naming "Checkpoint Inhibitor"
First trial start
2021
Mar 29, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Checkpoint Inhibitor", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor, Adult
- Cancer
- Neoplasms
- Sarcoma
- Sarcoma,Soft Tissue
- Chondrosarcoma
- Refractory Cancer
- Recurrent Cancer
Largest trials
Live from ClinicalTrials.gov: studies naming "Checkpoint Inhibitor" as an intervention, largest first.
Groupe Hospitalier Pitie-SalpetriereAcademic, hospital or other
NCT04294771 · 500,000 participants (planned) · Start Jan 1, 2019 · Primary completion Jan 1, 2030
Drug: ICI · For: Myocarditis; Cardiomyopathies; Heart Diseases and 3 more
Sites: Paris, France
Groupe Hospitalier Pitie-SalpetriereAcademic, hospital or other
NCT05934214 · 141,630 participants · Start Jan 1, 2023 · Primary completion Dec 31, 2023
Drug: Immune checkpoint inhibitor · For: Cancer; Immune-related Adverse Event; Immune Checkpoint Inhibitor-Related Myocarditis
Sites: Paris, France · 2 sites in all
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT07036016 · 67,818 participants · Start Jan 1, 2015 · Primary completion Dec 31, 2024
Drug: EGFR-TKI; PD-1/PD-L1 inhibitor and 1 more · For: Non-Small Cell Lung Cancer (NSCLC)
University Hospital, CaenAcademic, hospital or other
NCT04169503 · 17,562 participants (planned) · Start Oct 14, 2019 · Primary completion Jan 2020
Drug: Immune Checkpoint Modulator · For: Cancer
Sites: Caen, France
- Rechallenge of BRAF +/- MEK Inhibitors Following an Adverse Event in Patients With CancerStatus unknown
University Hospital, CaenAcademic, hospital or other
NCT05080361 · 16,000 participants (planned) · Start Jan 1, 2011 · Primary completion Mar 1, 2021
Drug: BRAF inhibitor · For: Cancer
Hunan Province Tumor HospitalAcademic, hospital or other
NCT05059951 · 15,000 participants (planned) · Start Oct 3, 2021 · Primary completion Sep 15, 2026
Drug: Immune checkpoint inhibitor · For: Non Small Cell Lung Cancer
Sites: Changsha, China
Guangxi Medical UniversityAcademic, hospital or other
NCT05221398 · 10,000 participants (planned) · Start Mar 3, 2019 · Primary completion Dec 18, 2030
Drug: Immune Checkpoint Inhibitors Based Adjuvant therapy · For: Hepatocellular Carcinoma
Sites: Nanning, China
- Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant ImmunotherapyActive, not recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07256002 · 10,000 participants (planned) · Start Jan 1, 2020 · Primary completion Dec 1, 2023
Drug: PD-1 Inhibitors; Chemotherapy and 1 more · For: Lung Cancer (NSCLC)
Sites: Beijing, China
Persephone BiosciencesIndustry
NCT04638751 · 5,000 participants (planned) · Start Jul 1, 2022 · Primary completion Dec 31, 2028
Drug: Immunotherapy; Chemotherapy · For: Non-small Cell Lung Cancer; Colorectal Cancer; Triple Negative Breast Cancer and 1 more
Sites: Orange, California; San Diego, California; Miami, Florida · 10 sites in all
Sungkyunkwan UniversityAcademic, hospital or other
NCT04115410 · 4,724 participants (planned) · Start Jul 1, 2020 · Primary completion Sep 23, 2021
Drug: PD-1 inhibitor; Chemotherapy Drugs, Cancer · For: Carcinoma, Non-Small-Cell Lung; Immune-Related Adverse Events
Newest research
PubMed records naming it or its code names, newest first.
- Autophagic stress-induced nanomedicine potentiates radioimmunotherapy against liver cancer through cGAS-STING signaling and immune remodeling.
Fang S, Zheng L, Hou D, et al. · Biomaterials 2027
- Outcomes of Patients with Rare Cancers Treated with Immune Checkpoint Inhibitors with and Without Lung and/or Liver Metastases (NCI/SWOG S1609).
Wang Y, Othus M, Chae YK, et al. · J Immunother Precis Oncol 2027
- Design, synthesis and biological evaluation of CYP1B1 targeted degraders for sensitizing immune checkpoint inhibitor therapy.
Wu Z, Hu L, Shi T, et al. · Eur J Med Chem 2027
- Seasonality and pandemic-era trends in Stevens-Johnson syndrome and toxic epidermal necrolysis: A pharmacovigilance and time series analysis.
Mukherjee EM, Park D, Asiaee A, et al. · J Allergy Clin Immunol Glob 2027
- Assessing the Antitumor Immune Effects of Gut Microbiota in a Preclinical Melanoma Model.
Sabaeifard P, Li W, Del Valle P, et al. · Methods Mol Biol 2027
- Assessment of Cell-Free MicroRNA by NGS Whole Transcriptome Analysis in Cutaneous Melanoma Patients' Blood.
Tran KD, Gross R, Rahimzadeh N, et al. · Methods Mol Biol 2027
Also in development for Solid Tumor, Adult
- VisugromabCTL-002, Visugromab RDEPhase 36 trials
CatalYm GmbH · Adult Solid Tumor, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Unresectable or Metastatic Hepatocellular Carcinoma
- anzutresgene autoleucelIMA203 Product, IMA203 product- flat dosePhase 32 trials
Immatics US, Inc. · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
- CRB-701Phase 32 trials
Corbus Pharmaceuticals Inc. · Solid Tumor, Adult, Oropharyngeal Carcinoma (OPC)
- HMPL-453Phase 32 trials
Hutchmed · Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult, Solid Tumor
- VT3989Phase 32 trials
Vivace Therapeutics, Inc · Pleural Mesothelioma, Mesothelioma, Solid Tumor, Adult
- DabogratinibTYRA-300Phase 24 trials
Tyra Biosciences, Inc · FGFR3 Gene Mutation, FGFR3 Gene Alteration, Achondroplasia
- VS-7375Phase 24 trials
Verastem, Inc. · G12D Mutated KRAS, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
- Tmod CAR T-cell TherapyA2B530, A2B694Phase 23 trials
A2 Biotherapeutics Inc. · Solid Tumor, Adult, Colorectal Cancer, Colorectal Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.